Related Experiment Videos
Glucocorticoid-induced osteoporosis
1Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK. jec1001@cam.ac.uk
Hormone Research
|December 13, 2003
Summary
Glucocorticoid therapy significantly raises osteoporosis and fracture risk, even at low doses and early in treatment. Bisphosphonates are effective in preventing this bone loss, especially for high-risk patients.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Background:
- Glucocorticoid therapy is a frequent cause of osteoporosis and fragility fractures.
- Increased fracture risk is observed even with low-dose and short-term glucocorticoid use.
- Bone loss affects both cortical and cancellous bone due to increased resorption and decreased formation.
Purpose of the Study:
- To review the impact of glucocorticoids on bone health.
- To discuss interventions for preventing glucocorticoid-induced bone loss.
- To provide guidance on managing bone density in patients on glucocorticoids.
Main Methods:
- Literature review of recent studies on glucocorticoid-induced osteoporosis.
- Analysis of evidence for various preventive interventions.
- Evaluation of risk factors and diagnostic criteria.
Main Results:
- Glucocorticoids increase fracture risk early and at low doses.
- Both bone resorption and formation are adversely affected.
- Bisphosphonates (etidronate, alendronate, risedronate) show the strongest evidence for prevention.
Conclusions:
- Primary prevention is recommended for high-risk individuals on oral glucocorticoids for ≥3 months (e.g., age ≥65, prior fracture).
- Bone densitometry should guide treatment decisions in other glucocorticoid-treated patients.
- Management strategies are crucial to mitigate skeletal complications of glucocorticoid therapy.